A58.F
Elevance Health, Inc.
FrankfurtEUREQUITY
Healthcare
DELAYED
Last price
338.00
▼ 2.50 (0.73%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
338.00
Prev close
340.50
Day high
338.00
Day low
338.00
Volume
37
Market cap
$73.30B
P/E (TTM)
17.49
52W range
240.60 – 375.70
Day trading desk
Gap from prior close
-0.73%
Prior close 340.50
VWAP
338.00
0.00% from price
Relative volume
37.00×
Unusually busy
Session range
—
338.00 – 338.00
Position in range
—
—
ATR (14D)
4.32
1.28% of price
Prior day high
340.50
PDH
Prior day low
340.50
PDL
Bid / ask spread
—
Quote not published
Session volume
37
Avg 1
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.77%
-0.4%
1M
-0.35%
-4.1%
3M
-0.35%
-3.5%
6M
+17.04%
+6.0%
YTD
+14.62%
+2.3%
1Y
+26.97%
+7.0%
3Y
-19.52%
-93.7%
5Y
+8.23%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on A58.F open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
412.05K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 17, 26 | PERU RAMIRO G Director |
BUY | 1.00K | $366.05K | Direct |
| Jul 17, 26 | BOUDREAUX GAIL A KOZIARA Chief Executive Officer |
BUY | 2.73K | $1.00M | Direct |
| Jun 12, 26 | PENCZEK RONALD W Officer |
SELL | 369 | $148.77K | Direct |
| Jun 11, 26 | DIXON ROBERT L JR Director |
SELL | 151 | $60.67K | Direct |
| May 19, 26 | PENCZEK RONALD W Officer |
CONVERSION | 1.53K | $450.58K | Direct |
| May 19, 26 | PENCZEK RONALD W Officer |
SELL | 1.53K | $617.19K | Direct |
| May 13, 26 | HAY LEWIS III Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | NERI ANTONIO F Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | JALLAL BAHIJA Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | STRABLE-SOETHOUT DEANNA D Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | SCHULMAN AMY W. Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | DIXON ROBERT L JR Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | DEVORE SUSAN D Director |
STOCK | 563 | $0 | Direct |
| May 13, 26 | SCHNEIDER RYAN M. Director |
STOCK | 563 | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOUDREAUX GAIL A KOZIARA |
Chief Executive Officer | 172.04K | Purchase |
BOUDREAUX GAIL KOZIARA |
Chief Executive Officer | 169.31K | Stock Award(Grant) |
DIXON ROBERT L JR |
Director | 10.73K | Sale |
HAY LEWIS III |
Director | 12.07K | Stock Award(Grant) |
HAYTAIAN PETER D |
Officer | 27.22K | Stock Award(Grant) |
KAYE MARK |
Chief Financial Officer | 32.04K | Stock Award(Grant) |
KENDRICK CHARLES MORGAN JR |
Officer | 11.79K | Sale |
LAVU RATNAKAR |
Chief Technology Officer | 16.15K | Stock Award(Grant) |
NORWOOD FELICIA F. |
Officer | 38.84K | Stock Award(Grant) |
PERU RAMIRO G |
Director | 10.91K | Purchase |
Fundamentals
Market cap$73.30B
Enterprise value$66.97B
Revenue (TTM)$201.11B
Gross profit$52.27B
EBITDA$8.32B
Net income$4.96B
EPS (TTM)$19.33
Free cash flow$4.31B
Total cash$37.51B
Total debt$31.04B
Book value / share$178.71
Shares outstanding216.87M
Float216.37M
Short % of float—
Dividend yield1.79%
Beta (5Y)0.69
Valuation & profitability ratios
Trailing P/E17.49
Forward P/E11.85
PEG ratio1.40
Price / sales—
Price / book1.89
EV / revenue0.33
EV / EBITDA8.05
Gross margin25.99%
Operating margin4.56%
Profit margin2.47%
Return on equity11.13%
Return on assets3.83%
Debt / equity68.95
Current ratio1.52
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $199.13B | $176.81B | $171.34B | $156.59B | — | +12.6% |
| Operating revenue | $199.13B | $176.81B | $171.34B | $156.59B | — | +12.6% |
| Selling, general & admin | — | — | — | $17.69B | $15.91B | — |
| Net interest income | -$1.40B | -$1.19B | -$1.03B | -$851.00M | — | -18.3% |
| Pre-tax income | $6.71B | $7.90B | $7.71B | $7.60B | — | -15.1% |
| Tax provision | $1.05B | $1.93B | $1.72B | $1.71B | — | -45.7% |
| Net income | $5.66B | $5.98B | $5.99B | $5.89B | — | -5.3% |
| Net income to common | $5.66B | $5.98B | $5.99B | $5.89B | — | -5.3% |
| Basic EPS | 25.65 | 26.29 | 25.69 | 25.32 | — | -2.4% |
| Diluted EPS | 25.21 | 25.68 | 25.22 | 24.81 | — | -1.8% |
| EBIT | $8.11B | $9.09B | $8.74B | $8.45B | — | -10.7% |
| Basic shares | 220.72M | 227.48M | 233.07M | 237.96M | — | -3.0% |
| Diluted shares | 224.60M | 232.90M | 237.40M | 242.80M | — | -3.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $9.49B | $8.29B | $6.53B | $7.39B | +14.5% |
| Cash & short-term investments | $35.38B | $33.49B | $36.14B | $33.34B | +5.6% |
| Accounts receivable | $10.07B | $8.01B | $7.90B | $7.08B | +25.7% |
| Property, plant & equipment | $4.68B | $4.65B | $4.36B | $4.32B | +0.6% |
| Goodwill & intangibles | $39.54B | $40.37B | $35.59B | $34.70B | -2.0% |
| Total assets | $121.49B | $116.89B | $108.93B | $102.75B | +3.9% |
| Long-term debt | $30.80B | $29.22B | $23.25B | $22.35B | +5.4% |
| Total debt | $32.05B | $31.23B | $25.12B | $24.11B | +2.6% |
| Total liabilities | $77.47B | $75.46B | $69.52B | $66.42B | +2.7% |
| Retained earnings | $35.39B | $33.55B | $31.75B | $29.65B | +5.5% |
| Shareholder equity | $43.88B | $41.31B | $39.31B | $36.24B | +6.2% |
| Net tangible assets | $4.34B | $944.00M | $3.72B | $1.54B | +359.5% |
| Shares issued | 220.72M | 227.48M | 233.07M | 237.96M | -3.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $5.66B | $5.97B | $5.99B | $5.89B | -5.2% |
| Depreciation & amortisation | $1.55B | $1.39B | $1.75B | $1.68B | +11.0% |
| Stock-based compensation | $276.00M | $191.00M | $289.00M | $264.00M | +44.5% |
| Change in working capital | -$3.28B | -$1.72B | -$535.00M | $423.00M | -90.6% |
| Operating cash flow | $4.29B | $5.81B | $8.06B | $8.40B | -26.1% |
| Capital expenditure | -$1.12B | -$1.26B | -$1.30B | -$1.15B | +11.1% |
| Investing cash flow | -$1.34B | -$5.17B | -$5.57B | -$4.56B | +74.0% |
| Share buybacks | -$2.60B | -$2.90B | -$2.68B | -$2.32B | +10.2% |
| Dividends paid | -$1.53B | -$1.51B | -$1.40B | -$1.23B | -1.4% |
| Financing cash flow | -$1.74B | $1.19B | -$3.35B | -$1.32B | -245.7% |
| Free cash flow | $3.17B | $4.55B | $6.76B | $7.25B | -30.3% |
| End cash position | $9.49B | $8.29B | $6.53B | $7.39B | +14.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $50.47B | $50.18B | $49.75B | $50.71B | $49.78B | — | +0.6% |
| Operating revenue | $50.47B | $50.18B | $49.75B | $50.71B | $49.78B | — | +0.6% |
| Net interest income | -$364.00M | -$357.00M | -$366.00M | -$351.00M | -$341.00M | — | -2.0% |
| Pre-tax income | $1.94B | $2.30B | $215.00M | $1.41B | $2.29B | — | -15.9% |
| Tax provision | $483.00M | $544.00M | -$331.00M | $219.00M | $548.00M | — | -11.2% |
| Net income | $1.46B | $1.76B | $547.00M | $1.19B | $1.74B | — | -17.1% |
| Net income to common | $1.46B | $1.76B | $547.00M | $1.19B | $1.74B | — | -17.1% |
| Basic EPS | 6.75 | 8.12 | 2.48 | — | 7.75 | 9.67 | -16.9% |
| Diluted EPS | 6.71 | 8.00 | 2.47 | — | 7.72 | 9.61 | -16.1% |
| EBIT | $2.30B | $2.66B | $581.00M | $1.76B | $2.63B | — | -13.5% |
| Basic shares | 216.84M | 217.37M | 220.72M | — | 225.20M | 226.40M | -0.2% |
| Diluted shares | 217.90M | 220.50M | 221.80M | — | 225.80M | 227.16M | -1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.23B | $9.66B | $9.49B | $8.71B | $8.56B | +6.0% |
| Cash & short-term investments | $35.95B | $35.56B | $35.38B | $35.00B | $33.86B | +1.1% |
| Accounts receivable | $10.99B | $11.53B | $10.07B | $9.54B | $10.46B | -4.6% |
| Property, plant & equipment | $4.64B | $4.66B | $4.68B | $4.66B | $4.64B | -0.3% |
| Goodwill & intangibles | $39.32B | $39.43B | $39.54B | $39.78B | $39.86B | -0.3% |
| Total assets | $126.44B | $125.83B | $121.49B | $122.75B | $121.94B | +0.5% |
| Current debt | $375.00M | $1.07B | $1.25B | $929.00M | $2.01B | -65.1% |
| Long-term debt | $30.67B | $30.77B | $30.80B | $31.17B | $28.18B | -0.3% |
| Total debt | $31.04B | $31.84B | $32.05B | $32.10B | $30.19B | -2.5% |
| Total liabilities | $81.42B | $81.78B | $77.47B | $78.67B | $78.09B | -0.5% |
| Retained earnings | $36.67B | $35.80B | $35.39B | $35.59B | $35.55B | +2.5% |
| Shareholder equity | $44.88B | $43.90B | $43.88B | $43.95B | $43.72B | +2.2% |
| Net tangible assets | $5.56B | $4.47B | $4.34B | $4.17B | $3.86B | +24.4% |
| Shares issued | 216.84M | 217.37M | 220.72M | 222.04M | 224.84M | -0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.45B | $1.76B | $546.00M | $1.19B | $1.74B | -17.4% |
| Depreciation & amortisation | $366.00M | $354.00M | $406.00M | $387.00M | $380.00M | +3.4% |
| Stock-based compensation | $75.00M | $55.00M | $30.00M | $84.00M | $81.00M | +36.4% |
| Change in working capital | $40.00M | $2.66B | -$524.00M | -$750.00M | -$218.00M | -98.5% |
| Operating cash flow | $1.91B | $4.33B | $84.00M | $1.14B | $2.05B | -55.8% |
| Capital expenditure | -$287.00M | -$235.00M | -$293.00M | -$360.00M | -$267.00M | -22.1% |
| Investing cash flow | $159.00M | -$1.64B | $464.00M | -$1.22B | -$687.00M | +109.7% |
| Share buybacks | -$234.00M | -$1.12B | -$471.00M | -$876.00M | -$378.00M | +79.2% |
| Dividends paid | -$373.00M | -$376.00M | -$377.00M | -$381.00M | -$385.00M | +0.8% |
| Financing cash flow | -$1.49B | -$2.52B | $236.00M | $243.00M | -$308.00M | +40.6% |
| Free cash flow | $1.63B | $4.10B | -$209.00M | $775.00M | $1.79B | -60.3% |
| End cash position | $10.23B | $9.66B | $9.49B | $8.71B | $8.56B | +6.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $49.12B | -1.9% |
| Next quarter | — | — | $48.12B | -2.4% |
| Current year | — | — | $196.24B | -0.7% |
| Next year | — | — | $200.39B | +2.1% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.19%
Held by institutions94.06%
Institutions holding2.16K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
341.22
-0.94% from price
SMA 20
336.55
+0.43% from price
SMA 50
343.47
-1.59% from price
SMA 100
328.48
+2.90% from price
SMA 200
305.52
+10.63% from price
EMA 12
339.63
-0.48% from price
EMA 26
339.91
-0.56% from price
EMA 50
338.52
-0.15% from price
RSI (14)
48.4
Neutral
MACD (12,26,9)
-0.28
Hist 0.66
ATR (14)
4.32
1.28% of price
Realised vol 30D
39.9%
Annualised
Bollinger upper
348.70
20, 2σ
Bollinger lower
324.39
20, 2σ
50 / 200 cross
Golden
343.47 vs 305.52
Trend bias
Above 200
+10.63%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.01
Less volatile than market
Correlation to SPY
-0.00
Largely independent
Realised vol 30D
39.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-26.1%
Peak to trough
Max drawdown 5Y
-57.2%
Peak to trough
ATR 14
4.32
1.28% of price
Beta (reported)
0.69
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 17, 26 | Leerink Partners | MAINTAINED | Market Perform | Market Perform |
| Jul 16, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Jul 16, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 16, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 16, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 16, 26 | Baird | MAINTAINED | Neutral | Neutral |
| Jul 14, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Jul 14, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jul 13, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jul 9, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Jul 7, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jul 2, 26 | Bernstein | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate$6.04 / yr
Forward yield1.79%
5-year avg yield1.37%
Payout ratio30.34%
Ex-dividend dateSep 10, 2026
Next pay date—
Last split—
Split date—
Headlines
Raphinha, Lopez hit braces as Barcelona trounce Elche
AFP · 13m ago
Amorim starts Serie A life with Milan win, Juve edge Frosinone
AFP · 17m ago
Lawsuit filed in Napali coast ‘doors-off’ helicopter tour crash
The Honolulu Star-Advertiser · 17m ago
Does Billionaire Bill Ackman Know Something Wall Street Doesn’t? He Invested in These 2 Stocks That Have Dropped 33% and 18% Over the Past Year
Motley Fool · 18m ago
Liquor industry struggles grow with another Chapter 7 filing
TheStreet · 20m ago
Media Advisory: Housing Announcement in Toronto
CNW Group · 23m ago
Dow Jones Futures Due With Market At Key Point; Nvidia, Tariffs, Warsh In Focus
Investor's Business Daily · 29m ago
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
Motley Fool · 33m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.